JP2024508890A5 - - Google Patents
Info
- Publication number
- JP2024508890A5 JP2024508890A5 JP2023553246A JP2023553246A JP2024508890A5 JP 2024508890 A5 JP2024508890 A5 JP 2024508890A5 JP 2023553246 A JP2023553246 A JP 2023553246A JP 2023553246 A JP2023553246 A JP 2023553246A JP 2024508890 A5 JP2024508890 A5 JP 2024508890A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- compound
- effective dose
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2021/051776 WO2022185097A1 (en) | 2021-03-03 | 2021-03-03 | Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508890A JP2024508890A (ja) | 2024-02-28 |
| JP2024508890A5 true JP2024508890A5 (https=) | 2024-03-13 |
Family
ID=74860360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553246A Withdrawn JP2024508890A (ja) | 2021-03-03 | 2021-03-03 | 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299376A1 (https=) |
| EP (1) | EP4301364A1 (https=) |
| JP (1) | JP2024508890A (https=) |
| KR (1) | KR20230154227A (https=) |
| CN (1) | CN117279639A (https=) |
| AU (1) | AU2021431485A1 (https=) |
| BR (1) | BR112023017689A2 (https=) |
| CA (1) | CA3212339A1 (https=) |
| MX (1) | MX2023010322A (https=) |
| WO (1) | WO2022185097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| CN118451068A (zh) * | 2021-12-30 | 2024-08-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
| US20220175760A1 (en) * | 2019-02-22 | 2022-06-09 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
-
2021
- 2021-03-03 BR BR112023017689A patent/BR112023017689A2/pt unknown
- 2021-03-03 JP JP2023553246A patent/JP2024508890A/ja not_active Withdrawn
- 2021-03-03 US US18/279,556 patent/US20240299376A1/en active Pending
- 2021-03-03 CN CN202180097818.8A patent/CN117279639A/zh active Pending
- 2021-03-03 AU AU2021431485A patent/AU2021431485A1/en not_active Abandoned
- 2021-03-03 MX MX2023010322A patent/MX2023010322A/es unknown
- 2021-03-03 KR KR1020237033580A patent/KR20230154227A/ko active Pending
- 2021-03-03 CA CA3212339A patent/CA3212339A1/en active Pending
- 2021-03-03 WO PCT/IB2021/051776 patent/WO2022185097A1/en not_active Ceased
- 2021-03-03 EP EP21710602.0A patent/EP4301364A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024508890A5 (https=) | ||
| USRE49556E1 (en) | Compounds and compositions as protein kinase inhibitors | |
| JP2016523973A5 (https=) | ||
| EA005423B1 (ru) | Противовирусные композиции | |
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| HRP20241633T1 (hr) | 2,4-disupstituirani derivat pirimidina, postupak njegove pripreme i njegova uporaba | |
| EA032421B1 (ru) | Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| BR112020022553A2 (pt) | benzamidas substituídas por 1,3-tiazol-2-ila para o tratamento de doenças associadas com a sensibilização de fibras nervosas | |
| RU2014142057A (ru) | Комплексная терапия | |
| JP2018531288A5 (https=) | ||
| CN116406355A (zh) | P38α促分裂原活化蛋白激酶抑制剂 | |
| JP2022535850A5 (https=) | ||
| CN117062819A (zh) | 多环化合物及其用途 | |
| JP2022520361A5 (https=) | ||
| JP2024518685A5 (https=) | ||
| JP2023501584A5 (https=) | ||
| JP2023536996A (ja) | アデノシン受容体アンタゴニストの併用療法 | |
| CN107753486B (zh) | 含1,6-二取代吲哚化合物的低抗药性低副作用慢性骨髓性白血病治疗剂 | |
| WO2018186366A1 (ja) | 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤 | |
| WO2022051589A1 (en) | Cocrystals of an adenosine a2b receptor antagonist | |
| CN106279176B (zh) | 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用 | |
| JP7540946B2 (ja) | アシルチオウレア化合物とアビラテロンの併用療法 | |
| RU2023131966A (ru) | Кристаллические формы свободного основания (S,E)-4-(диметиламино)-N-(3-(4-(2-гидрокси-1-фенилэтиламино)-6-фенилфуро[2,3-d]пиримидин-5-ил)фенил)бут-2-енамида | |
| WO2022171018A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| NZ770629A (en) | Pyridopyrimidinone derivatives for use as axl inhibitors |